Case 38-2014: An 87-Year-Old Man with Sore Throat, Hoarseness, Fatigue, and Dyspnea ( Case Records of the Massachusetts General Hospital, N Engl J Med 2014;371:2321-2327 ) . In the Cancer subsection of Differential Diagnosis (page ... New England Journal of Medicine, 3 days ago
Case 38-2014: An 87-Year-Old Man with Sore Throat, Hoarseness, Fatigue, and Dyspnea - New England Journal of Medicine, 3 days ago
European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA® (ibrutinib) to Treat..
/PRNewswire/ --Pharmacyclics, Inc. (NASDAQ: PCYC) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending a change to the terms of the marketing ...ADVFN India, 2 days ago Pharmacyclics Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia BioSpace, 1 day ago Pharmacyclics (PCYC) Release: European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA (ibrutinib) To Treat Waldenstrom's Macroglobulinemia 5/22/2015 ClinicSpace, 1 day ago New ibrutinib (IMBRUVICA®) Data to be Showcased at American Society of Clinical Oncology (ASCO) Annual Meeting TickerTech.com, 1 week ago
More from: Town Hall, Town Hall...and 46 other sources
0 Flares 0 Flares × What happens when you give children everything they ask for? They get spoiled, of course. Any parent can tell you that. The problem is that youre trying to raise children to (eventually) be responsible adults. Part of ...PM 360, 1 day ago
SAN DIEGO — Patients with nickel allergy and severe refractory symptoms after implantation with an atrial septal closure device experienced complete resolution of symptoms after device explantation, according to a report presented at the Society ...Orthopedics Today, 1 day ago
Merck & Co. Receives Positive Opinion For KEYTRUDA (pembrolizumab) For The Treatment Of Advanced Melanoma
KENILWORTH, N.J.--( BUSINESS WIRE )--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has ...BioSpace, 1 day ago Merck Receives Positive CHMP Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced Melanoma World Energy Source, 2 days ago Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Nivolumab (Opdivo, Nivolumab BMS) for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer in Previously-Treated Patients Pharmacy Choice, 1 day ago Merck & Co. (MRK) Receives Positive CHMP Opinion For KEYTRUDA (pembrolizumab) For The Treatment Of Advanced Melanoma 5/22/2015 ClinicSpace, 1 day ago
/PRNewswire/ -- Today,Novartis announced for the first time detailed results from its phase III EXPEDITION trial program for QVA149 (indacaterol/glycopyrronium) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the ...ClinicSpace, 3 days ago Novartis Investigational Drug Significantly Improved Lung Function PharmaceuticalProcessing, 3 days ago Novartis investigational dual bronchodilator significantly improved lung function compared to single bronchodilators in patients with moderate-to-severe COPD in phase III studies Scottrade, 3 days ago Novartis announces two positive US phase III programs in COPD for QVA149 and NVA237 EuroInvestor, 3 days ago
Genentech reported positive results from two pivotal studies (NP28673 and NP28761) that showed alectinib, its oral investigational anaplastic lymphoma kinase (ALK) inhibitor, shrank tumors (overall response rate; ORR: 50.0 percent and 47.8 percent, ...4 Traders, 2 days ago Genentech Reports Positive Results from 2 Pivotal Studies on alectinib Individual.com, 6 days ago ROCHE BEARER SHARE : Genentech Reports Positive Results from 2 Pivotal Studies on alectinib 4 Traders, 6 days ago Roche announces positive results from two pivotal studies of alectinib which shrank tumours with specific type of lung cancer PharmaBiz, 1 week ago
Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emerge
Despite several critical steps forward in the management of chronic heart failure (CHF), the area of acute heart failure (AHF) has remained relatively stagnant. As stated in the updated ESC HF guidelines, clinicians responsible for managing patients ...European Heart Journal, 2 days ago
0 Flares 0 Flares × FROM ANNALS OF VASCULAR SURGERY Cardiac and vascular surgery patients should receive deep vein thrombosis (DVT) prophylaxis before and after surgery, say researchers who found a high incidence of postoperative DVT in ...PM 360, 3 days ago
Positive results have been announced from the phase III development program for QVA149 (indacaterol/glycopyrronium, Novartis) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). In the U.S., QVA149 and glycopyrronium ...P&T Community, 3 days ago
on your WebpageAdd Widget >Get your members hooked!